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j ourna l homepage: www.e lsev ie r .com/ locate /atg“Toward a systemplan for transforming cancer care to amolecular-based
approach”: Recommendations from an expert panelLeading cancer experts convened for a one day Think Tank to devel-
op practical recommendations for transforming cancer care from an
organ-based approach to a molecular-based approach. The event took
place on May 30, 2013 in Chicago prior to ASCO and was keynoted by
Dr. Richard Wilson, Director, The Genome Institute at Washington Uni-
versity School of Medicine.
Members
• Rick Wilson, Director, The Genome Institute at Washington Univ. School
of Medicine
• Judy Garber, Director, Cancer Risk/Prevention Clinic, Dana Farber
• Shashikant Kulkarni, Head of Clinical Genomics, Wash. University School
of Medicine
• Shyamali Singhal, Medical Director of the Cancer Center, El Camino Hos-
pital
• Nickolas Papadopoulos, Director of Translational Genetics, Johns Hopkins
Medicine
• John Sweetenham, CMO, Huntsman Cancer Institute
• Paula Rieger, CEO, Oncology Nurses Society
• Nazneen Aziz, Director of Molecular Medicine, College of American Pa-
thologists
• Mary Zutter, Director, Tumor-Host Interaction Program, Vanderbilt
Ingram Cancer Center
• Tim McDaniel, Director of Scientiﬁc Research, Illumina Inc.
• Les Paul, CMO, Caris Life Science
• Dawn Van Dam, CEO, Health Connexions
• Anthony Flynn, Associate, AcceleratorH
Think Tank Background
At the 2011 Personalized Medicine Conference1 at Harvard Medical
School, 80% of attendees voted “genomic interpretation” as the top chal-
lenge in adopting genomics in routinemedical care. Given the industry-
wide collaboration involved in interpretation, an I-Study2 set out to de-
termine howwell the healthcare ecosystem is aligned with the goals of
genomic medicine and to offer recommendations to accelerate this im-
portant advance.
The 2012 I-study conducted interviews with more than 55 industry
leaders across twelve healthcare sectors: pharmaceuticals, contract re-
search organizations, academic laboratories, commercial laboratories, di-
agnostic companies, decision support suppliers, healthcare providers,
sequencing providers, healthcare equipment makers, care management,1 An annual two-day event co-hosted andpresented by PartnersHealthCare Personalized
Medicine, Harvard Business School, and Harvard Medical School in association with the
American Association for Cancer Research and the Personalized Medicine Coalition.
2 Interpretation study directed by Cambridge Healthtech Associates and GenomeQuest,
Inc. and co-sponsored by the Personalized Medicine Coalition.
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2212-0661/© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-Nhealthcare IT, and payers. An expert panel representing science, medical,
technology, and business disciplines reviewed the transcripts and pro-
duced a comprehensive set of ﬁndings and recommendations.
One of the recommendations, originally suggested by Dr. Rick Wilson
ofWashingtonUniversity,was: “Prepare a SystemPlan forMolecular-based
Treatment of Cancer”. Many interviewees felt that cancer is best treated as
a molecular disorder and not an organ disorder and reported frustration
with the present mismatch between a molecular approach and the
organ-based structure of the present healthcare system. Hence, a study
recommendation called for a systematic plan to transform cancer care
based on the current molecular understanding of the disease, speciﬁcally
that cancer is more similar across organs than previously understood.
Recommendations
1. Establish a shared, sustainable registry of patient/tumor pheno-
types/genotypes for use by the cancer research and care community.
Clinical genomics relies upon the collection of statistically valid data
that is collected and analyzed to identify patterns and draw conclusions.
Both the research and clinical members felt strongly that cancer care
would beneﬁt greatly if there was a shared, sustainable, de-identiﬁed reg-
istry of patient/tumor phenotypes/genotypes for use by all. Armed with
this expanding collection of data, clinical teams could look for similar pro-
ﬁles to guide patient diagnosis and treatmentwhile research could gain an
aggregation of rich, clinical-grade data to drive discovery.
Several requirements were discussed. First, because patients and
care organizations are hesitant to contribute their samples and related
data to a for-proﬁt organization, the registry should be run by a non-
proﬁt organization. Second, in order to be self-sustaining ﬁnancially,
the registry should have a governance program that clariﬁes use and es-
tablishes membership costs and compensation — organizations that
consume and beneﬁt should pay and fund the registry and organiza-
tions that contribute the data should receive payment to fund the re-
quired overhead. Third, at the outset, the registry should provide
unanalyzed genotype data and basic phenotype data with importing/
exporting tools and grow to provide a framework for users to apply
their own analysis tools and store/share intermediate results and ﬁnd-
ings. Fourth, at the outset, the data types and ﬁelds should start with
rawDNA sequence results (with a quality threshold) and available phe-
notype data. The system should, over time, scale to accept multi-
sample/tumor/normal results, multiple types of test results (DNA,
RNA, imaging), and increasingly rich phenotype information.
Today, the vast majority of cancer sequencing results are not captured
and applied to general research. This registry and its broadusewould offer
the beneﬁt of a “feedback loop” into genomic cancer care where the large
volume of payer-subsidized, clinical-quality tests would indeed be cap-
tured and applied back into research by the entire cancer community.
Timeframe goal: A pilot organization, plan, and funding from pharma
and foundations in 2014.C-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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verages the efforts of groups creating related collaborations, including:NCI
NCCs, CGHub, CDISC, Project Data Sphere, TCGA, and CHTN. These groups
offer critical knowledge, expertise, and perhaps infrastructure and data to
accelerate the registry's start and improve its long-term impact.
2. Provide physician decision-support on the latest diagnostic/
treatment options and reimbursement guidelines.
With rapid developments in molecular-based cancer care, physi-
cians are forced to spend too much time researching new diagnostic/
treatment options and related reimbursement policies. Ideally, payers
could work toward providing cancer care decision support in these
areas that could be applied to patient cases — improving outcomes
and reducing time and costs. Such a system would ideally track the
latest diagnostic/treatment options, provide proﬁle-speciﬁc standard-
of-care workﬂows, and offer payer-speciﬁc reimbursement guidelines.
Timeframe goal: A working system from the majority of payers by
2015.
Candidate organizations to lead: Large payer(s), payer organization,
or payer system supplier.
3. Deﬁne evidence required during this transition period.
In transitioning from organ-based care to molecular-based care, the
cancer care community currently lacks clarity on what evidence is re-
quired to achieve standard of care in both clinical and payer arenas.
The lack of clarity leaves a void that is slowing advancement, creating in-
efﬁciencies, and discouraging investment. Until clarity is attained, the re-
search community seeks transitionary guidelines for such evidence. Such
guidelines would expand investment and discoveries, improve care, and
accelerate the advance to a more stable state of cancer care.
Timeframe goal: A draft set of guidelines and parameters by 2015.
Candidate organizations to lead: NCCN lead, working in concert with
payers and payer organizations.
4. Redeﬁne clinical study methodologies to match the new
realities and opportunities.
Traditionally, clinical study methodologies have been deﬁned for
and applied to large populations with non-mutating disorders. On the
other hand, molecular diagnostics, treatments, and strategies for cancer
care target smaller populations and disorders that rapidly mutate. This
new understanding calls for studies that are smaller, more agile and
time-sensitive, include molecular biomarkers, involve integrated diag-
nostics and treatment, and expand the domain of study to include test
algorithms and treatment strategies. Overall, the situation calls for a re-
deﬁnition of clinical study methodologies.
Timeframe goal: A credible organization commits to lead this effort
by 2015.
Candidate organizations to lead: Patient-Centered Outcomes Re-
search Institute (PCORI).
5. Identify wheremarket is failing to develop required/sustainable
business models and propose solutions.
The transition to a molecular-based approach to cancer care is a
promising one; full of breakthrough scientiﬁc and medical opportuni-
ties. New types of companies, businessmodels, investments and leader-
ship are likely needed. We call on a leading business school to identify
where thismarket is failing to organically develop new sustainable busi-
ness models and propose strategies for success.
Timeframe goal: A comprehensive and funded study begins in 2015.
Candidate organizations to lead: A major business school.
6. Prepare the cancer care community for new care delivery
associated with molecular-based treatment.
TheUS spends over $100B3 on cancer care annuallywith over 20,0004
professionals serving over 1.6M new patients and 13M5 surviving
patients.3 NIH: “Projections of the Cost of Cancer Care in the United States: 2010–2020”.
4 ASCOU.S. membership numbers, including oncologists, surgeons, radiologists, pathol-
ogists, and nurses.
5 American Cancer Society: “Cancer Facts & Figures 2013”.Molecular-based treatment is fast becoming the focus of advanced
cancer care and needs to be built into themainstream practice of cancer
care. As it is a relatively new and rapidly advancing ﬁeld, care profes-
sionals and primary care physicians, particularly outside of academic
medicine, need to be trained on the fundamentals and kept abreast of
the latest developments.We propose a proﬁciency and continuing edu-
cation program for each of these care providers.
Beyond the basics of molecular medicine, examples of new topics to
cover:
• workﬂows to diagnose and treat different molecular proﬁles/patterns
• the integrated set of diagnostic readings, including: genotype, trans-
criptomes, epigenomes, and imaging
• drugs that treat at a molecular level and are effective across organs
• the need for “waves of diagnosis and treatment” to battle “waves of
mutations”
Timeframe goal: A comprehensive and funded study begins in 2015.
Candidate organizations to lead: ASCO.
7. Perform an economic impact analysis
In an integrated healthcare model, it would be straightforward to
measure and prove that a holistic, molecular testing/treatment ap-
proach leads to improved outcomes and overall cost cutting. However,
given the fragmented nature of US healthcare, providers across the
spectrum ﬁnd it difﬁcult to prove these beneﬁts to policy makers,
payers, and investors.
The situation calls for an economic analysis ofmolecular-based diag-
nosis/treatment of cancer care — ideally, an observational study based
on costs and results over a signiﬁcant period on a population of patients.
Such a reportwould informpayers on guidelines for caseworkﬂows and
diagnostic/treatment reimbursement. To guide and accelerate the
study, it should be conducted in conjunction with an accountable care
organization (ACO), which could serve as a pilot for implementing and
measuring value-based policies.
Timeframe goal: A study is structured and commences in 2015.
Candidate organizations to lead: Major payer, ideally in partnership
with a major ACO.
8. Build on success of clinical/scientiﬁc partnerships.
Some of the most advanced molecular-based cancer care treatment
comes from clinical centers in close partnership with research groups;
examples discussed include those at Vanderbilt University, El Camino
Hospital, andWashington University. These collaborations offer signiﬁ-
cant advantages to both sides; researches have close connections to real
cases, care providers can apply the latest discoveries, and often the two
collaborate directly on patient diagnosis and treatment. Great beneﬁt
could come from understanding the structural lessons learned of these
partnerships so they can be broadly applied across the cancer care com-
munity, including the formation ofmore partnerships between industry
(companies invested in molecular proﬁling) and the academic research
community. Ultimately, it's the patients who will beneﬁt with broader
access to leading-edge cancer care.
Timeframe goal: A think tank to study and document lessons learned
in clinical/scientiﬁc partnerships.
Candidate organizations to lead: Cambridge Healthtech Associates
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